Reprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical models
Science Translational Medicine · 03.06.2026 · 18 (852)
DOI: 10.1126/scitranslmed.aea0189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 03.06.2026. Verfasst von Peina Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory for Drug Delivery Nanocarriers, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beij…. Hauptthemen laut MEDLINE: Dinoprostone, Phosphatidylserines, Apoptosis, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, National Key R&D Program of China Nos.
Abstract (Originalsprache)
Uncontrolled hemorrhage in trauma, surgical, organ-related, and endoscopic settings, particularly in patients receiving antiplatelet therapy, remains difficult to manage clinically. Here, we introduce a high phosphatidylserine (PS)–exposed procoagulant platelet (hPPL) derivative reprogrammed from isolated platelets via calcium ionophore A23187–induced apoptosis, enriched in surface PS and capable of driving rapid hemostasis. Retaining a protein profile akin to resting platelets, hPPLs robustly promoted platelet activation and aggregation in human- and rat-derived plasma and whole blood in vitro and demonstrated superior hemostatic efficacy compared with clinical thrombin and commercial hemostatic materials [microporous polysaccharide hemispheres (MPH) and FIBRILLAR] in murine liver injury and porcine gastric ulcer bleeding models, even under antiplatelet treatment. Mechanistically, hPPLs up-regulated prostaglandin E synthase (PTGES), thereby increasing prostaglandin E2 (PGE 2 ) production and its receptor 3 (EP3)–mediated platelet activation, which reinforced PS-mediated clot formation. Our findings identified an apoptosis-driven PTGES-PGE 2 -EP3 signaling axis that augmented PS-mediated coagulation in murine and porcine hemorrhage models and established the hPPL derivative as a topical hemostatic agent with translational potential for organ-related bleeding and distinct advantages in managing complex endoscopic hemorrhages under both physiological and coagulopathic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory for Drug Delivery Nanocarriers, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
- Department of Histology and Embryology, College of Basic Medical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, Ministry of Education Key Laboratory of Molecular and Cellular Biology, College of Life…
- College of Materials Science and Opto-Electronics Technology, College of Nanoscience and Engineering, School of Advanced Interdisciplinary Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
- Division of Gastroenterology and Hepatology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100084, China.
ORCID-Profile: Peina Wang, Shuailun Du, Suying Wu, Yaqi Zhai, Ammara Safdar, Zhenyu Liu, Zefang Lu, Bozhao Li, Rui Zhang, Zexian Zeng, Guangjun Nie, Yan-Zhong Chang, Suping Li
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- National Key R&D Program of China Nos
- CAS Project for Young Scientists in Basic Research
- Beijing Natural Science Foundation Economic-Technological Development Area Innovation Joint Fund
Zitieren
APA
Wang, P., Du, S., Wu, S., Zhai, Y., Bai, J., Safdar, A., Liu, Z., Lu, Z., Li, B., Cheng, J., Song, Y., Zhang, R., Li, D., Wang, Z., Zeng, Z., Nie, G., Chang, Y. Z., & Li, S. (2026). Reprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical models. Science Translational Medicine, 18(852). https://doi.org/10.1126/scitranslmed.aea0189
Vancouver
Wang P, Du S, Wu S, Zhai Y, Bai J, Safdar A, et al. Reprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical models. Science Translational Medicine. 2026;18(852). doi:10.1126/scitranslmed.aea0189
BibTeX
@article{Wang2026,
author = {Wang, Peina and Du, Shuailun and Wu, Suying and Zhai, Yaqi and Bai, Jiawei and Safdar, Ammara and Liu, Zhenyu and Lu, Zefang and Li, Bozhao and Cheng, Jin and Song, Yuchang and Zhang, Rui and Li, Dandan and Wang, Zhicheng and Zeng, Zexian and Nie, Guangjun and Chang, Yan-Zhong and Li, Suping},
title = {Reprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical models},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {852},
doi = {10.1126/scitranslmed.aea0189}
}
EUVIMED